EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET ANALYSIS

Regional Analysis

Global Epigenetics Drugs & Diagnostic Technologies Market - Regional Analysis

Among region, North America is estimated to hold a dominant position in the global epigenetics drugs & diagnostic technologies market over the forecast period, owing to increasing launches of technologies. For instance, according to an article published in Journal of Cell Biology on April 9, 2021, researchers at UC San Francisco and the Whitehead Institute, a U.S.-based non-profit research institute, described a novel CRISPR-based tool called “CRISPRoff,” which allows scientists to switch off almost any gene in human cells without making a single edit to the genetic code. The researchers also showed that once a gene is switched off, it remains inert in the cell’s descendants for hundreds of generations, unless it is switched back on with a complementary tool called CRISPRon, also described in the paper.

Geographies covered:

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa

Based on region, the global epigenetics drugs & diagnostic technologies market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among these, North America segment is expected to dominate the market over the forecast period due to increasing research and development for newer epigenetic technologies in this region.